Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial

Antoine Leimgruber, Sandrine Ostermann, Eun J. Yeon, Evelyn Buff, Philippe P. Maeder, Roger Stupp, Reto A. Meuli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Purpose: This study was performed to determine the impact of perfusion and diffusion magnetic resonance imaging (MRI) sequences on patients during treatment of newly diagnosed glioblastoma. Special emphasis has been given to these imaging technologies as tools to potentially anticipate disease progression, as progression-free survival is frequently used as a surrogate endpoint. Methods and Materials: Forty-one patients from a phase II temolozomide clinical trial were included. During follow-up, images were integrated 21 to 28 days after radiochemotherapy and every 2 months thereafter. Assessment of scans included measurement of size of lesion on T1 contrast-enhanced, T2, diffusion, and perfusion images, as well as mass effect. Classical criteria on tumor size variation and clinical parameters were used to set disease progression date. Results: A total of 311 MRI examinations were reviewed. At disease progression (32 patients), a multivariate Cox regression determined 2 significant survival parameters: T1 largest diameter (p < 0.02) and T2 size variation (p < 0.05), whereas perfusion and diffusion were not significant. Conclusion: Perfusion and diffusion techniques cannot be used to anticipate tumor progression. Decision making at disease progression is critical, and classical T1 and T2 imaging remain the gold standard. Specifically, a T1 contrast enhancement over 3 cm in largest diameter together with an increased T2 hypersignal is a marker of inferior prognosis.

Original languageEnglish (US)
Pages (from-to)869-875
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number3
StatePublished - Mar 1 2006


  • Diffusion
  • Glioblastoma
  • Magnetic resonance imaging
  • Perfusion
  • Progression

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial'. Together they form a unique fingerprint.

Cite this